Diagnostics company Guardant Health (NASDAQ:GH) in Q2 CY2025, with sales up 30.9% year on year to $232.1 million. The company ...

A groundbreaking study reveals that Guardant Reveal's liquid biopsy detects immunotherapy responses earlier, enhancing ...

Guardant Health partners with actor James Van Der Beek to promote early colorectal cancer screening through the Shield blood ...

Second Quarter 2025 Results Key Financial Results Revenue: US$232.1m (up 31% from ...

James Van Der Beek was diagnosed with colon cancer in 2023. He hopes more people will get screened earlier with the new ...

James Van Der Beek and Guardant are partnering for a campaign focused on colorectal cancer. Guardant Health announced a ...

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will participate in the ...

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced its partnership with actor and ...

Discover Guardant Health's FDA breakthroughs & revenue growth! Learn why profitability-focused investors might hold back ...

James Van Der Beek, whose net worth is $6 million, as per Celebrity Net Worth, has partnered with Guardant Health to raise ...

Guardant Health, Inc. ( NASDAQ: GH) Q2 2025 Earnings Conference Call July 30, 2025 4:30 PM ET AmirAli Talasaz - Co-CEO & Director Helmy Eltoukhy - Co-Founder, Co-CEO & Chairman Michael Bell - Chief ...

PALO ALTO, Calif. (AP) — PALO ALTO, Calif. (AP) — Guardant Health Inc. (GH) on Wednesday reported a loss of $99.9 million in its second quarter. The Palo Alto, California-based company said it had a ...